Free tool
FAERS Monitor: Natesto
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205488 or its brand name (Natesto, Testosterone). Reports on generic versions are filed under their own applications.
Reports
19,198
Serious
10,945
57% of reports
Hospitalization
4,611
Death reported
780
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,489
- off label use1,238
- fatigue1,186
- nausea862
- headache788
- pain777
- diarrhoea630
- anxiety614
- asthenia599
- arthralgia598
- dizziness596
- dyspnoea552
- insomnia517
- weight decreased433
- depression428
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 169 |
| 2005 | 126 |
| 2006 | 139 |
| 2007 | 156 |
| 2008 | 188 |
| 2009 | 248 |
| 2010 | 307 |
| 2011 | 334 |
| 2012 | 875 |
| 2013 | 367 |
| 2014 | 556 |
| 2015 | 1,113 |
| 2016 | 1,060 |
| 2017 | 984 |
| 2018 | 1,193 |
| 2019 | 1,247 |
| 2020 | 1,199 |
| 2021 | 1,219 |
| 2022 | 1,422 |
| 2023 | 1,553 |
| 2024 | 1,642 |
| 2025 | 1,729 |
| 2026 | 1,372 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,961 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anxietySignal | 614 | 2.4 | 2.2 | 489 |
| insomniaSignal | 517 | 2.1 | 2.0 | 312 |
| depressionSignal | 428 | 2.1 | 1.9 | 235 |
| asthenia | 599 | 1.7 | 1.6 | 194 |
| weight decreased | 433 | 1.7 | 1.5 | 126 |
| fatigue | 1,186 | 1.7 | 1.6 | 330 |
| arthralgia | 598 | 1.6 | 1.5 | 128 |
| off label use | 1,238 | 1.5 | 1.5 | 251 |
| pain | 777 | 1.4 | 1.3 | 86 |
| headache | 788 | 1.4 | 1.3 | 84 |
| dizziness | 596 | 1.3 | 1.2 | 44 |
| drug ineffective | 1,489 | 1.2 | 1.2 | 72 |
| nausea | 862 | 1.2 | 1.1 | 28 |
| diarrhoea | 630 | 1.1 | 1.0 | 3 |
| dyspnoea | 552 | 1.1 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.